Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2012

View Archived Issues

Novel shRNA molecule demonstrates potential efficacy for patients with mesothelioma

Enrollment commences in new phase II study of ELND-005

TAS-114 demonstrates promising antitumor activity in combination with other oncolytic agents

Selecta Biosciences and Sanofi sign global collaboration to develop allergy immunotherapies

AiCuris begins second trial of pritelivir for genital herpes

GW Pharmaceuticals identifies novel oral cannabinoid candidate for type 2 diabetes

Novel, orally bioavailable HSP 90 inhibitor developed by Taiho for cancer

Phase I and II data reveal efficacy of AMG-145

Linaclotide receives European marketing approval for IBS-C

New APE-1 inhibitors presented by U.S. Department of Health & Human Services

Usher III Initiative prepares novel compounds for Usher syndrome

Polish group designs novel agents for HCMV infection

Researchers at Merck & Co. disclose new B-raf inhibitors

APY-0201 significantly ameliorates skin inflammation in animal models of psoriasis

ElexoPharm and Merck & Co. cooperate on novel series of CYP11B2 inhibitors

FDA accepts tivozanib NDA filing

Safety and pharmacokinetic phase I data reported for MGL-3196

NovImmune begins phase I study of NI-0101

NICE recommends Bronchitol for adults with cystic fibrosis

Mochida Pharmaceutical patents new GRP40 receptor agonists

Novel heat shock protein HSP 90 inhibitor prodrugs prepared at Myrexis

NICE recommends ivabradine for patients with chronic heart failure

Coronado Biosciences begins phase I/II trial of CNDO-109

NPS licenses rights to teduglutide in Israel to Neopharm

First clinical data on RG-7212 show target modulation and signs of efficacy

Biotron begins extended preclinical toxicology studies of BIT-225

FDA committee recommends accelerated approval of bedaquiline NDA

Kowa and Sanwa Kagaku Kenkyusho set to launch Suiny in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...